Thomas Furmanak
Associate Director, Translational Medicine Cabaletta Bio
Seminars
Wednesday 2nd December 2026
Evaluating No Preconditioning Approaches in Autoimmune Therapies
2:00 pm
- Mechanistic basis of activity and safety of resecabtagene autoleucel across multiple autoimmune diseases
- Incorporating potential updates from lupus studies to provide a broader perspective on applicability across indications
- Assessing how removing preconditioning could reshape clinical adoption and plenary-level discussion within the field
